Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Phase II Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

NCT06234748 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT06234748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06234748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Phase II Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 20, 2023
Completion date
July 31, 2028
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related carcinoma, oropharynx cancer